DDW Highlights: 7 April 2026

The U.S. Food and Drug Administration granted accelerated approval to Avlaya, the first FDA‑approved biologic engineered to cross the blood‑brain barrier. Designed as an enzyme‑replacement therapy for Hunter syndrome, Avlaya achieved a 91 % reduction in cerebrospinal fluid heparan sulfate, a surrogate marker linked to neurologic decline. By normalizing this biomarker in more than 90 % of treated children, the therapy promises to shift the standard of care for a disease that has lacked a brain‑penetrant option for two decades. Clinicians anticipate earlier intervention could preserve cognitive function and quality of life.

In parallel, Eli Lilly announced a definitive agreement to acquire Centessa Pharmaceuticals for roughly $1 billion upfront, adding a pipeline of orexin‑2 receptor agonists that target the master switch of the sleep‑wake cycle. The deal underscores growing investor confidence in neuro‑pharmacology. Meanwhile, Mount Sinai’s AI‑driven co‑scientist BiomniAD captured the $1 million Alzheimer’s Insights AI Prize, demonstrating how multimodal data integration can compress research timelines from months to minutes. Complementing these advances, the PRISM ALS consortium launched a global repository of patient‑derived induced pluripotent stem cell models, aiming to reduce the high attrition rate in ALS drug trials.

The FDA also approved Lifioli, the first selective glucocorticoid receptor antagonist, in combination with Napakolitic Cell for platinum‑resistant ovarian, fallopian tube, and primary peritoneal cancers. The Rosella trial showed a 35 % reduction in mortality and a median overall survival gain of 4.1 months versus chemotherapy alone. This approval highlights a broader trend toward precision agents that sensitize tumors to existing regimens. Together, these milestones illustrate a rapid acceleration of innovative therapies across rare genetics, neuroscience, AI‑enabled discovery, and oncology, reshaping the drug‑development landscape.